Corticosteroids: Options in the era of steroid-sparing therapy

被引:119
作者
Del Rosso, J
Friedlander, SF
机构
[1] Univ Nevada, Sch Med, Dept Dermatol, Las Vegas, NV 89154 USA
[2] Univ Calif San Diego, Sch Med, Dept Med Dermatol, San Diego, CA 92103 USA
[3] Univ Calif San Diego, Sch Med, Dept Pediat, San Diego, CA 92103 USA
[4] Childrens Hosp, San Diego, CA USA
关键词
D O I
10.1016/j.jaad.2005.04.030
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Topical corticosteroids remain the most commonly used topical treatments for inflammatory dermatoses, including psoriasis and atopic dermatitis. Topical corticosteroids are available in a variety of vehicle-screams, ointments, lotions, gels, and, more recently, foam. The vehicle used can substantially affect the individual agent's clinical action, potency, and acceptability to the patient. Moreover, some vehicles are better suited for specific body areas. Selection of the appropriate product should be determined by area of usage, physician experience, cost, and patient preference, particularly regarding vehicle. Although topical corticosteroicts are associated with several side effects, including skin atrophy, telangiectases, pUrpura, and striae formation, appropriate usage can minimize these Occurrences. judicious use includes short-term, appropriate application as initial monotherapy or in combination strategies with other therapeutic agents that ideally possess complementing mechanisms of action. Examples include pulsing with high-potency Z, topical corticosteroids and combination regimens with other topical agents such as topical calcineurin inhibitors, calcipotriene, or tazarotene. Appropriate education of patients and caregivers alike will facilitate the optimal use of these medications.
引用
收藏
页码:S50 / S58
页数:9
相关论文
共 59 条
[51]  
Stoughton RB, 1992, TOPICAL CORTICOSTERO, P42
[52]  
TANOJO H, 2000, 61 ANNM AM AC DERM
[53]   Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema [J].
Thomas, KS ;
Armstrong, S ;
Avery, A ;
Po, ALW ;
O'Neill, C ;
Young, S ;
Williams, HC .
BRITISH MEDICAL JOURNAL, 2002, 324 (7340) :768-771
[54]  
Torok HM, 2003, CUTIS, V72, P161
[55]  
TROZAK DJ, 1990, CUTIS, V46, P341
[56]  
Trozak DJ, 1999, CUTIS, V64, P315
[57]   CASE OF GROWTH RETARDATION AND CUSHINGS-SYNDROME DUE TO EXCESSIVE APPLICATION OF BETAMETHASONE-17-VALERATE OINTMENT [J].
VERMEER, BJ ;
HEREMANS, GFP .
DERMATOLOGICA, 1974, 149 (05) :299-304
[58]   Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect [J].
Weinstein, GD ;
Krueger, GG ;
Lowe, NJ ;
Duvic, M ;
Friedman, DJ ;
Jegasothy, BV ;
Jorizzo, JL ;
Shmunes, E ;
Tschen, EH ;
LewKaya, DA ;
Lue, JC ;
Sefton, J ;
Gibson, JR ;
Chandraratna, RAS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (01) :85-92
[59]  
WITTEN VH, 1992, TOPICAL CORTICOSTERO, P1